<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971187</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1266</org_study_id>
    <secondary_id>NCI-2021-07070</secondary_id>
    <nct_id>NCT04971187</nct_id>
  </id_info>
  <brief_title>Bintrafusp Alfa With Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Locally Advanced or Metastatic Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer</brief_title>
  <official_title>A Single-Arm Phase 2 Study to Investigate Bintrafusp Alfa With Platinum-Pemetrexed for TKI-Resistant EGFR-Mutant NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of bintrafusp alfa with pemetrexed and platinum-based&#xD;
      chemotherapy (carboplatin or cisplatin) in treating patients with EGFR mutant non-small cell&#xD;
      lung cancer that have spread to nearby tissue or lymph nodes (locally advanced) or other&#xD;
      places in the body (metastatic) and cannot be removed by surgery, and remains despite&#xD;
      treatment with tyrosine kinase inhibitors (Resistant). Immunotherapy with bintrafusp alfa, a&#xD;
      bifunctional fusion protein composed of the monoclonal antibody anti-PD-L1 and TGF-beta, may&#xD;
      help the body's immune system attack the cancer, and may interfere with the ability of tumor&#xD;
      cells to grow and spread. Pemetrexed may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth. Chemotherapy drugs, such as carboplatin and cisplatin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells, by&#xD;
      stopping them from dividing, or by stopping them from spreading. Giving bintrafusp alfa with&#xD;
      pemetrexed and platinum-based chemotherapy may help to control the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best objective response rate</measure>
    <time_frame>Within 6 months since initiation of treatment</time_frame>
    <description>Will be provided with 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>At 18 weeks since initiation of treatment</time_frame>
    <description>Will be provided with 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <description>Adverse event data will be summarized by type, severity grade, and attribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolve toxicities</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response rate</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Cox proportional hazards regression analysis or logistic regression will be used to correlate the time-to-event endpoints such as PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Cox proportional hazards regression analysis or logistic regression will be used to correlate the time-to-event endpoints such as OS.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma</condition>
  <condition>Metastatic Lung Non-Squamous Non-Small Cell Carcinoma</condition>
  <condition>Stage III Lung Cancer AJCC v8</condition>
  <condition>Stage IIIA Lung Cancer AJCC v8</condition>
  <condition>Stage IIIB Lung Cancer AJCC v8</condition>
  <condition>Stage IIIC Lung Cancer AJCC v8</condition>
  <condition>Stage IV Lung Cancer AJCC v8</condition>
  <condition>Stage IVA Lung Cancer AJCC v8</condition>
  <condition>Stage IVB Lung Cancer AJCC v8</condition>
  <condition>Unresectable Lung Non-Squamous Non-Small Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bintrafusp alfa IV over 1 hour on day 1 and pemetrexed IV over 10 minutes on day 1. Patients also receive carboplatin IV over 15 minutes or cisplatin IV over 6-8 hours at the physician's discretion on day 1 of cycles 1-4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp Alfa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)</arm_group_label>
    <other_name>1918149-01-5</other_name>
    <other_name>Anti-PDL1/TGFb Trap MSB0011359C</other_name>
    <other_name>M7824</other_name>
    <other_name>MSB0011359C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)</arm_group_label>
    <other_name>137281-23-3</other_name>
    <other_name>L-Glutamic Acid</other_name>
    <other_name>N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)</other_name>
    <other_name>MTA</other_name>
    <other_name>Multitargeted Antifolate</other_name>
    <other_name>Pemfexy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)</arm_group_label>
    <other_name>(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O'']platinum</other_name>
    <other_name>1-cyclobutanedicarboxylic acid platinum complex</other_name>
    <other_name>41575-94-4</other_name>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)</other_name>
    <other_name>Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum</other_name>
    <other_name>cis-diammine(cyclobutanedicarboxylato)platinum II</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>platinum</other_name>
    <other_name>diammine(1,1-cyclobutanedicarboxylato(2-))-</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)</arm_group_label>
    <other_name>(SP-4-2)-Diamminedichloroplatinum</other_name>
    <other_name>15663-27-1</other_name>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Diaminedichloro-</other_name>
    <other_name>cis- (8CI)</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age equal or greater than 18 years old and willing to give their signed consent&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-squamous, non-small cell lung cancer&#xD;
&#xD;
          -  Locally advanced or metastatic disease, not amenable to curative surgery or&#xD;
             radiotherapy&#xD;
&#xD;
          -  Patients must have one of the following:&#xD;
&#xD;
               -  NSCLC which harbors EGFR Exon 19 deletion.&#xD;
&#xD;
               -  NSCLC which harbors EGFR L858R mutation.&#xD;
&#xD;
               -  NSCLC which harbors EGFR G719X, S768X, L861X mutation, and other activating&#xD;
                  uncommon mutations in exon 18-21&#xD;
&#xD;
               -  NSCLC which harbors EGFR exon20 insertion&#xD;
&#xD;
               -  NSCLC which harbors EGFR T790M mutation EGFR deletion/mutation must be documented&#xD;
                  by a Clinical Laboratory Improvement Amendments (CLIA) certified test&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  At least one target lesion, not previously irradiated and not chosen for biopsy during&#xD;
             the study screening period, that can be accurately measured at baseline at equal or&#xD;
             greater than 10 mm in the longest dimension by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) 1.1&#xD;
&#xD;
          -  Patients must have received at least one line of EGFR tyrosine kinase inhibitor (TKI)&#xD;
             treatment, if an Food and Drug Administration (FDA)-approved treatment exist for the&#xD;
             EGFR mutation. Patients whose tumor harboring EGFR T790M mutation must have received&#xD;
             prior osimertinib (or another EGFR TKI with demonstrated activity against T790M&#xD;
             mutation). Patients who received more than one EGFR TKIs are eligible. Up to two lines&#xD;
             of TKIs are allowed&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3 (obtained less than 4 weeks from study&#xD;
             entry)&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3 (obtained less than 4 weeks from study entry)&#xD;
&#xD;
          -  Hemoglobin (HgB) &gt;= 9 g/dL (obtained less than 4 weeks from study entry)&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x upper limit of normal (ULN) (obtained less than 4 weeks from study&#xD;
             entry)&#xD;
&#xD;
          -  International normalized ratio (INR) =&lt; 1.5 and partial thromboplastin time (PTT)&#xD;
             (PTT/activated partial thromboplastin time [aPTT]) &lt; 1.5 x upper limits of normal&#xD;
             (ULN) (obtained less than 4 weeks from study entry). Patients receiving warfarin must&#xD;
             be switched to low molecular weight heparin and have achieved stable coagulation&#xD;
             profile prior to first dose of protocol therapy&#xD;
&#xD;
          -  Total serum bilirubin =&lt; 1.5 x ULN (patients with known Gilbert Syndrome, a total&#xD;
             bilirubin =&lt; 3.0 x ULN, with direct bilirubin =&lt; 1.5 x ULN) (obtained less than 4&#xD;
             weeks from study entry)&#xD;
&#xD;
          -  Serum glutamic-oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase&#xD;
             (SGPT) =&lt; 3 X ULN if no liver metastasis present (obtained less than 4 weeks from&#xD;
             study entry)&#xD;
&#xD;
          -  SGOT, SGPT =&lt; 5 X ULN if liver metastasis present (obtained less than 4 weeks from&#xD;
             study entry)&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV): stable on antiretroviral therapy (ART) for at&#xD;
             least 4 weeks, no documented evidence of multi-drug resistance, viral load of &lt; 400&#xD;
             copies/ml and CD4+ T-cells =&lt; 350 cells/uL (obtained less than 4 weeks from study&#xD;
             entry)&#xD;
&#xD;
          -  Hepatitis B virus (HBV)/hepatitis C virus (HCV): participant on a stable dose of&#xD;
             antiviral therapy, HBV viral load below the limit of quantification. HCV viral load&#xD;
             below the limit of quantification (obtained less than 4 weeks from study entry)&#xD;
&#xD;
          -  Females of childbearing potential must not be breast feeding and must have a negative&#xD;
             serum or urine pregnancy test within 7 days of starting of treatment. The patient must&#xD;
             agree to use adequate contraception for a minimum of two weeks prior to receiving&#xD;
             study medication until 65 days after discontinuation of the study medication.&#xD;
             Acceptable methods of contraception include total and true sexual abstinence, hormonal&#xD;
             contraceptives that are not prone to drug-drug interactions (IUS levonorgestrel intra&#xD;
             uterine system [Mirena], medroxyprogesterone injections [Depo-Provera]), copper-banded&#xD;
             intra-uterine devices, and vasectomized partner. All hormonal methods of contraception&#xD;
             should be used in combination with the use of a condom by their sexual male partner.&#xD;
             Females of childbearing potential are defined as those who are not surgically sterile&#xD;
             (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or&#xD;
             postmenopausal (defined as 12 months with no menses without an alternative medical&#xD;
             cause). Women will be considered post-menopausal if they have been amenorrheic for the&#xD;
             past 12 months without an alternative medical cause. The following age-specific&#xD;
             requirements must also apply: women &lt; 50 years old: they would be considered&#xD;
             post-menopausal if they have been amenorrheic for the past 12 months or more following&#xD;
             cessation of exogenous hormonal treatments. The levels of luteinizing hormone (LH) and&#xD;
             follicle-stimulating hormone (FSH) must also be in the post-menopausal range (as per&#xD;
             the institution). Women &gt;= 50 years old: they would be consider post-menopausal if&#xD;
             they have been amenorrheic for the past 12 months or more following cessation of all&#xD;
             exogenous hormonal treatments, or have had radiation-induced oophorectomy with the&#xD;
             last menses &gt; 1 year ago, or have had chemotherapy-induced menopause with &gt; 1 year&#xD;
             interval since last menses, or have had surgical sterilization by either bilateral&#xD;
             oophorectomy or hysterectomy&#xD;
&#xD;
          -  Non-sterilized males who are sexually active with a female partner of childbearing&#xD;
             potential must use adequate contraception for the duration of the study and 125 days&#xD;
             after the last dose of study medication. Adequate contraception methods include: birth&#xD;
             control pills (e.g. combined oral contraceptive pill), barrier protection, and&#xD;
             abstinence. Patients should not father a child for 125 days after completion of the&#xD;
             study medication. Patients should refrain from donating sperm from the start of dosing&#xD;
             until 125 days after discontinuing the study medication. If male patients wish to&#xD;
             father children they should be advised to arrange for freezing of sperm samples prior&#xD;
             to the start of the study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatments with cytotoxic chemotherapy or checkpoint immunotherapy or&#xD;
             combination of chemo-immunotherapy for metastatic disease. If the patient had prior&#xD;
             chemotherapy as neoadjuvant or adjuvant therapy, the completion of treatment must be&#xD;
             greater than 6 months until the beginning of the treatment on trial&#xD;
&#xD;
          -  Previous treatment with any anti-TGF-beta medications&#xD;
&#xD;
          -  Spinal cord compression or brain metastases unless asymptomatic or stable for at least&#xD;
             2 weeks prior to start of study treatment&#xD;
&#xD;
          -  Persisting grade &gt; 1 Common Terminology Criteria for Adverse Events (CTCAE) 5.0&#xD;
             toxicity (except alopecia and vitiligo) related to prior therapy; however, sensory&#xD;
             neuropathy grade =&lt; 2 is acceptable&#xD;
&#xD;
          -  Current use of immunosuppressive medication, EXCEPT for the following:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injection (e.g.,&#xD;
                  intra-articular injection);&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses =&lt; 10 mg/day of prednisone or&#xD;
                  equivalent;&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., computed&#xD;
                  tomography [CT] scan premedication).&#xD;
&#xD;
          -  Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory&#xD;
             agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid&#xD;
             diseases not requiring immunosuppressive treatment are eligible&#xD;
&#xD;
          -  Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior&#xD;
             history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids&#xD;
&#xD;
          -  No previous malignant disease within the last 3 years except for a.&#xD;
             superficial/non-invasive bladder cancer, or basal or squamous cell carcinoma in situ&#xD;
             treated with curative intent; b. endoscopically resected gastrointestinal (GI) cancers&#xD;
             limited to the mucosal layer without recurrence in &gt; 1 year&#xD;
&#xD;
          -  No prior organ transplantation including allogenic stem-cell transplantation, except&#xD;
             transplants that do not require immunosuppression&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Live vaccination that has received or will receive within 30 days prior to the first&#xD;
             administration of study intervention. Seasonal flu vaccines that do not contain a live&#xD;
             virus are permitted. COVID-19 vaccines are permitted&#xD;
&#xD;
          -  Known severe hypersensitivity (grade &gt;= 3 National Cancer Institute [NCI] CTCAE 5.0)&#xD;
             to investigational product or any component in its formulations, any history of&#xD;
             anaphylaxis, or recent, within 5 months, history of uncontrollable asthma&#xD;
&#xD;
          -  Clinically significant (i.e., active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months&#xD;
             prior to enrollment), unstable angina, congestive heart failure (&gt;= New York Heart&#xD;
             Association Classification class II), or serious cardiac arrhythmia requiring&#xD;
             medication&#xD;
&#xD;
          -  History of bleeding diathesis or recent major bleeding events (i.e. grade &gt;= 2&#xD;
             bleeding events in the month prior treatment)&#xD;
&#xD;
          -  Males and females of reproductive potential who are not using and effective method of&#xD;
             birth control and females who are pregnant or breastfeeding or have a positive (urine&#xD;
             or serum) pregnancy test prior to study entry. Females who are pregnant or&#xD;
             breast-feeding&#xD;
&#xD;
          -  Judgment by the investigator that the patient should not participate in the study if&#xD;
             the patient is unlikely to comply with study procedures, restrictions and requirement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuning Le</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuning Le</last_name>
    <phone>713-792-6980</phone>
    <email>Xle1@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuning Le</last_name>
    </contact>
    <investigator>
      <last_name>Xiuning Le</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

